Determining treatment intensity in elderly patients with multiple myeloma. Salvini M et al. Expert Rev Anticancer Ther. 2018 Sep. doi: 10.1080/14737140.2018.1496823. [Epub 2018 Jul 13] Treatment patterns and medication adherence among patients diagnosed with multiple myeloma and treated with panobinostat. Chari A et al. Future Oncol. 2018 Sep. doi: 10.2217/fon-2017-0727. [Epub 2018 May 30] Autologous stem cell transplantation in first…
The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets. Abramson HN. Clin Lymphoma Myeloma Leuk. 2018 Sep. doi: 10.1016/j.clml.2018.06.015. [Epub 2018 Jun 18] A new conceptual framework for the therapy by optimized multidimensional pulses of therapeutic activity. The case of multiple myeloma model. Horvath D and Brutovsky B. J Theor Biol. 2018 Oct 7. doi: 10.1016/j.jtbi.2018.06.015. [Epub 2018 Jun…
Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study. Cella D et al. Ann Hematol. 2018 Sep 4. doi: 10.1007/s00277-018-3469-4. [Epub ahead of print] Bilateral Angle Closure Following the Infusion of a Monoclonal Antibody to Treat Relapsing Multiple Myeloma. Lee AC et al. J…
Bone Health and Survival in Women With Multiple Myeloma.
Rosko AE et al. Clin Lymphoma Myeloma Leuk. 2018 Sep. doi: 10.1016/j.clml.2018.06.002. [Epub 2018 Jun 8]
Clarithromycin as the empiric antibiotic therapy for medication-related osteonecrosis of the jaw in multiple myeloma patients. Zadik Y. Oral Oncol. 2018 Sep. doi: 10.1016/j.oraloncology.2018.07.016. [Epub 2018 Jul 29.] Proteasome inhibitors for multiple myeloma. Okazuka K and Ishida T. Jpn J Clin Oncol. 2018 Sep 1. doi: 10.1093/jjco/hyy108. The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets.…
Early salivary changes in multiple myeloma patients undergoing autologous HSCT.
van Leeuwen S et al. Oral Dis. 2018 Sep. doi: 10.1111/odi.12866
Vos JM et al. J Neurol Neurosurg Psychiatry. 2018 Sep. doi: 10.1136/jnnp-2017-316689.
This month Myeloma UK published a new research report recommending that researchers, the NHS and healthcare professionals work together to improve the way that patient reported outcome measures (PROMs) are utilised in myeloma research. PROMs are questionnaires that are completed by patients and are often used either in a clinical trial setting to measure the impact of a…
Addition of doxycycline to ciprofloxacin for infection prophylaxis during autologous stem cell transplants for multiple myeloma. Sivik JM et al. Support Care Cancer. 2018 Mar 21. doi: 10.1007/s00520-018-4165-6. [Epub ahead of print]. Evaluation of the relevance of surgery in patients with multiple myeloma harboring symptomatic spinal involvement: a retrospective case series. Quidet M et al. World Neurosurg. 2018 Mar 9. pii: S1878-8750(18)30458-3. doi: 10.1016/j.wneu.2018.02.184.…
The impact of the introduction of bortezomib on dialysis independence in multiple myeloma patients with renal impairment: a nationwide Dutch population-based study. Oortgiesen BE et al. Haematologica. 2018 Mar 15. pii: haematol.2017.184754. doi: 10.3324/haematol.2017.184754. [Epub ahead of print]. Multiple Myeloma Presenting as a Superscan on 68Ga-Pentixafor PET/CT. Pan Q et al. Clin Nucl Med. 2018 Mar 13. doi: 10.1097/RLU.0000000000002067. [Epub ahead of…
Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC. Augeul-Meunier K et al. Bone Marrow Transplant. 2018 Mar 9. doi: 10.1038/s41409-018-0122-8. [Epub ahead of print]. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation…